secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-042955
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook
----------------------------------------------------------------------------

- Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).
- CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.
- Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.
- FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).
- FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/0001104659-25-042955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465925042955/tm2513742d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-042955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer